Introduction {#Sec1}
============

Pituitary adenomas are the second mos t prevalent central nervous system tumors (24.6%) \[[@CR1]\]. Patients often present with visual deficits related to chiasmal compression such as visual field deficits (46--75%) and decreased visual acuity (14--44%) \[[@CR2]--[@CR6]\]. Both of these presenting symptoms are associated with a lower health-related quality of life (HRQoL) in this patient group and are therefore seen as a clear indication for surgery \[[@CR4], [@CR7]\].

While the aim of surgical resection in patients presenting with visual deficits is to improve or halt further progression of these deficits, possible complications may result in permanent worsening of the same symptoms \[[@CR3]\]. Since the introduction of endoscopic endonasal transsphenoidal surgery (EETS), postoperative visual outcomes have improved \[[@CR5], [@CR8], [@CR9]\]. However, results of visual outcomes vary, and worsening of symptoms or even new deficits have been reported as well \[[@CR10], [@CR11]\]. As it is unclear what the effect of EETS is on visual outcomes and which determinants may influence these outcomes, variation in treatment strategy and timing of surgery between practices has been reported \[[@CR4], [@CR12]\]. Some centers operate on pituitary adenomas only to alleviate current visual complaints, whereas others operate with the goal to prevent the development of future symptoms and progression of existing symptoms \[[@CR4], [@CR12]\].

Due to variation in treatment strategy, including timing of the procedure, visual function after endoscopic endonasal surgery for pituitary tumors may vary among patients. Therefore, the primary aim of this meta-analysis was to document more precise prevalence rates of postoperative improvement, complete recovery, and deterioration of visual function. The secondary aim of this study was to identify and assess determinants, especially the effect of surgical timing, of postoperative visual functioning.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

This meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement \[[@CR13]\]. After approval of the protocol, the following databases were searched on 07-08-2016 for relevant literature: PubMed, Embase, Cochrane, Central, CINANHL, PsycINFO, Academic Search Premier, ScienceDirect and Web of Science. The search strategy was based on the keywords: "pituitary", "endoscopic surgery" and "vision" and search terms to exclude studies with only animals, case reports and reviews (Supplementary Table 1). In addition, articles published before 1992 were excluded, as the first report on endoscopic endonasal pituitary surgery was published in that year \[[@CR14]\].

Paper selection {#Sec4}
---------------

Titles and abstracts of articles were screened by two independent authors for eligibility. Discrepancies were solved by a third author. Inclusion criteria were original peer-reviewed articles in English, describing visual outcomes after endoscopic endonasal transsphenoidal pituitary adenoma surgery in patients older than 18 years. Articles that described outcomes after pituitary apoplexy and results of resection with extended endoscopic approaches were excluded. Furthermore, case-reports, congress abstracts, commentaries and reviews were excluded. If there were overlapping cohorts, only the largest cohort was included in the review. References of selected articles were checked for possible relevant studies. Disagreements were solved by discussion.

Data extraction {#Sec5}
---------------

The following study characteristics were extracted from the full text articles: study design, main in- and exclusion criteria, number of participants, gender, age, tumor subtypes, tumor size, and gross total resection rate. Regarding the visual outcomes, the following data were extracted: time between diagnosis and surgery, and pre- and postoperative visual outcomes. If visual outcomes were specified by the included studies for visual acuity and visual field deficits, the number of patients that showed complete recovery, general improvement or deterioration was extracted for these specific outcomes. If outcomes were not specified for visual acuity and visual fields deficits, data were extracted for unspecified visual function. In addition, determinants of postoperative visual outcomes were extracted from the included studies.

Study quality assessment of the included studies {#Sec6}
------------------------------------------------

Study quality was assessed using the Newcastle--Ottawa scale for cohort studies and the criteria for case series by Cowley \[[@CR15], [@CR16]\]. Criteria of both scales were combined and adapted for the subject of this study (Supplementary Table 2). Studies were assessed for patient selection (max. 4 points), exposure of intervention (i.e. surgery: max. 1 point) and outcome assessment (max. 5 points).

Meta-analysis {#Sec7}
-------------

Pooled prevalence of complete recovery, improvement and deterioration were assessed for visual acuity, visual fields deficits or unspecified visual functioning using Comprehensive meta-analysis CMA^©^ version 3. Fixed overall prevalence rates were calculated using the inverse variance method and random prevalence rates using the method of DerSimonian and Laird \[[@CR17]\]. Fixed prevalence rates were reported in text if not further specified. Study heterogeneity was assessed by calculating I-squared values. An I-squared value \>40% was deemed high. Furthermore, publication bias was assessed with Begg's test and Egger's test. In case of significant publication bias, a corrected fixed prevalence rate was calculated using the trim and fill method \[[@CR18]\]. Meta-regression on covariates such as study characteristics was not possible, as these were not reported in all studies. Therefore, factors influencing visual outcomes as described in the included articles are qualitatively described. To assess the effect of study quality on the reported visual outcomes, a meta-regression was conducted with study quality as covariate.

Results {#Sec8}
=======

Study characteristics {#Sec9}
---------------------

After removing duplicates, 2636 articles were identified. After screening for title and abstract 2398 articles were excluded and 238 articles were reviewed full text. Afterwards, 35 studies were included in the review and meta-analysis (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR5], [@CR6], [@CR8]--[@CR11], [@CR19]--[@CR47]\]. All studies were retrospective case series. The total number of participants ranged between 10 and 313 (median: 45). Mean age per study ranged between 35.5 and 72.5 years (median: 50) and the percentage female patients ranged between 15 and 100% (median: 45%). Seven studies included only non-functioning pituitary adenoma patients \[[@CR28], [@CR31], [@CR33], [@CR37], [@CR40], [@CR42], [@CR46]\]. Gross total resection grades were reported in 26 studies and ranged between 14 and 91% (median: 63.5%) (Table [1](#Tab1){ref-type="table"}) \[[@CR5], [@CR6], [@CR8], [@CR11], [@CR20], [@CR21], [@CR24]--[@CR26], [@CR28]--[@CR34], [@CR36]--[@CR40], [@CR42], [@CR43], [@CR46], [@CR47]\].

Fig. 1Flowchart of search strategy

Table 1Study characteristicsAuthor (year)Study designMain in- and exclusion criteriaSample size endoscopic patientsAge in years mean (SD)/median (range)Number female (%)Tumor subtypesTumor sizeGross total resectionStudies reporting both visual acuity and visual field deficit Bokhari (2013)Retrospective case seriesInclusion: PA, fully endoscopic transsphenoidal surgery (1998--2010)79Mean age: 56.7 (SD: 16.3)44 (56%)NF 39 (49%), PRL 16 (20%), GH 19 (24%), ACTH 4 (5), TSH 1 (1)NS50 (63%) Campbell (2010)Retrospective case seriesInclusion: GH producing adenomas (2005--2009)26Mean age: 45.7 (--)12 (46%)GH (100%)84.6% ≥10 mm: 84.6%26 (73%) Chabot (2015)Retrospective case seriesInclusion: adenoma size \>3 cm (2009--2014)39Median age: 56.3 (SD: 15.6)14 (40%)NS\>4 cm: 15.6%NS Juraschka (2014)Retrospective case seriesInclusion: PA patients (2006--2012) maximum tumor diameter in any plane ≥3 cm, and tumor volume ≥10 cm^3^. Exclusion: lack of suprasellar growth73Mean: 55 (SD: 15)23 (32%)NF 65 (89%) functioning 6 (8.2%), unknown: 2 (2.8%)Mean: 4.09 cm73 (24%) Karppinen (2015)Retrospective case seriesInclusion: NFPA patients (2000--2011) endoscopic and transnasal. Exclusion: craniectomy, re-resection, hormonally active adenomas and pituitary carcinoma41/18558.5 (SD: 16)18 (44%)NF 185 (100%)Mean: 27 (SD: 9)23 (41%) Yildrim (2016)Retrospective case seriesInclusion: NFPA pure endoscopic endonasal transsphenoidal technique (2009--2014)160Mean age 49 (--)72 (45%)NF: 160 (100%)Mean: 2.48 cm (--)160 (90%)Studies only reporting visual acuity Constantino (2016)Retrospective case seriesInclusion: PAs with diameter \>3 cm (2010--2014)28Mean age: 46 (--)11 (40%)NSMean: 4.6 cm (--)28 (14%) De Witte (2011)Retrospective case seriesInclusion: PA resected endoscopic transsphenoidal (2007--2010)83Mean age: 50 (--)39 (47%)NF 40 (48.3%), PRL 6 (7.2%), GH 6 (7.2%), ACTH 3 (3.6%), TSH 1 (1.2%), mixed 17 (20.5%)73 Macroadenomas83 (30%) Fan (2014)Retrospective case seriesInclusion: PA resections (2005--2010)28Median age: 43 (--)17 (60%)NF 17 (60.1), PRL 5 (17.9%), GH 3 (10.7%), ACTH 2 (7.2%) mixed: 1 (3.6%)25 \>1 cm28 (57%)Studies only reporting visual field deficit Anik (2011)Retrospective case seriesInclusion: PA with visual field deficits. Exclusion: comorbidity that can influence vision (2009--2010)72Mean age: 45.7 (SD: 10.9)43 (57%)NF 42 (58.3), PRL 6 (8.3%), GH 22 (30.5%), ACTH 2 (2.8%)NSNS Akin (2016)Retrospective case seriesInclusion: prolactinomas reected endonasally (2006--2012)142Mean age: 35.5 (SD: 13.3)76 (54%)PRL 142 (100%)113 Macroadenomas, 10 giant adenomasNS Cappabianca (1999)Retrospective case seriesInclusion: pituitary adenoma, microscopic (1996) endoscopic (1997)10/30Range: 33--674 (40%)NF 5 (50%), GH 5 (50%)7 Microadenomas9 (90%) Chi (2013)Retrospective case seriesInclusion: PA with endonasal extension (2011--2012)80Mean age: 51 (--)35 (44%)NF 24 (30%), PRL 26 (32.5%), GH 9 (11.3%), ACTH 3 (3.8%), TSH 3 (3.8%), mixed 5 (6.3%)16 Microadenomas80 (64%) Cho (2002)Retrospective case seriesInclusion: cohort of endoscopic and sublabial resection of prolactinomas (1996--2000)22/44Mean age: 45 (--)22 (100%)PRL 22 (100%)NSNS Dallapiazza (2015)Retrospective case seriesInclusion: NFPA patients with \>5 year follow-up80Mean age: 57 (SD: 13)42 (53%)NF 80 (100%)31 \> 3.0 cm80 (71%) Dehdashti (2008)Retrospective case seriesInclusion: PA patients, purely endoscopic endonasal operation (2004--2007). Exlcusion: very large pituitary adenomas and extended approaches200Mean age 50 (--)109 (55%)NF 111 (55.5%), PRL 25 (12.5%), GH 34 (17%), ACTH 27 (13.5), TSH 3 (1.5)NS182 (97%) D'Haens (2009)Retrospective case seriesInclusion: pituitary adenoma resected microscopic (1995--2001), endoscopic (2001--2007)60/120Mean age 37 (--)41 (68%)PRL 29 (48%), GH 13 (23%), ACTH 16 (27%), TSH 2 (3%)NSNS Leach (2010)Retrospective case seriesInclusion: sellar lesions (2005--2007) operated endoscopically89/125NSNSNF 67 (54%), PRL 9 (7%), GH 22 (18%), ACTH 10 (8%), craniopharyngioma 4 (3%), Other 7 (6%)NSNS Minet (2008)Retrospective case seriesInclusion: PA with \>6 month follow-up (2003--2005)31/71Mean age: 51.4 (17.2) (endonasal)14 (45%) (endonasal)NF 27 (87%) PRL 2 (7%), TSH: 1 3 (%), GH: 1 (3%)NSNS Nakao (2011)Retrospective case seriesInclusion: giant NFPA endonasal resection (2000--2008)43Mean age: 55 (--)20 (47%)NF 43Mean diameter: 47.8 mm (SD 1.2)20 (47%) Paluzzi (2014)Retrospective case seriesInclusion: purely endoscopic operated PA patients (2002--2011)555NSNF 360 (69.2), PRL 53 (10%), GH 49 (10%), ACTH 58 (11%)89.4% \>1 cm359 (65%) Sheehan (1999)Retrospective case seriesInclusion: NFPA endonasal resection (1995--1997)26/70Mean age: 59.2 (SD: 15.1)8 (31%)NSVolume: 11.0 (SD: 6.9) cm^3^NSStudies reporting unspecified visual function Chohan (2016)Retrospective case seriesInclusion: PAs with size \>10 cm^3^ or cross sectional length \>4 cm (2003--2014)62Mean age 54 (--)27 (44%)NSMedian volume: 13.74 cm^3^62 (47%) Cusimano (2012)Retrospective case seriesInclusion: giant pituitary adenomas (\>10 cm^3^) resected endoscopically or by craniotomy or microscopically (1994--2001)29/72Mean age 50 (SD: 15)13 (45%)NF 25 (83%), functioning 4 (17%)Mean: 4.0 cm26 (91%) Gondim (2014)Retrospective case seriesInclusion: giant pituitary adenomas \>4 cm (1998--2011)50Mean age: 48.2 (--)17 (34%)NF 42 (80%) GH 5 (10%) PRL 3 (6%)\>4 cm50 (38%) Gondim (2015)Retrospective case seriesInclusion: NFPA exclusion: previous surgery, age \>70 (2000--2012)55Mean age: 72.5 (SD: 2)23 (42%)NF 55 (100%)Mean size 33 mm (SD: 23)55 (78%) Ferreli (2014)Retrospective case seriesInclusion: NFPA with cavernous sinus invasion. Exclusion: grade 1 and 2 according to Knosp; patients who had previously been treated with radiotherapy in the pituitary region; patients with follow-up shorter than 36 months. (2000--2010)56median: 59 (37--79)20 (36%)NF 56 (100%)34 \> 1 cm, 22 \> 4 cm17/56 (30%) Han (2013)Retrospective case seriesInclusion: PA, endoscopic endonasal approach (2009--2012)250Mean age: 43.8 (--)151 (60%)NF 147 (58.8%), PRL 33 (13.2%), GH 42 (16.8%), ACTH 20 (8%), TSH 3 (1.2%), mixed 5 (2%)116 Macroadenomas250 (86%) Jho (1997)Retrospective case seriesInclusion: PA endoscopic endonasal approach (1993--1995)15Median age: 43 (range 17--88)9 (60%)NF 6 (40%), PRL 5 (33.3%), ACTH 3 (20%), adenoma 1 (6.7%)NSNS Koutourousiou (2013)Retrospective case seriesInclusion: giant PA with diameter \>4 cm (2002--2011)54Mean age: 53 (--)8 (15%)NSMean: 32.88 cm^3^ (--)11 (20%) Kuo (2016)Retrospective case seriesInclusion: giant PA size (\> 4 cm in at least 1 direction or estimated tumor volume \> 10 cm^3^) (2002--2009)38Mean age: 51 (SD: 13)23 (60%)NSMean: 3.2 cm^3^ (SD: 4.6)38 (21%) Marenco (2011)Retrospective case seriesInclusion: PA: \>65 years old, non-functioning (2001--2013)25Mean age: 72 (SD: 5)14 (56%)NF 25 (100%)Mean: 3.4 cm (SD: 7.3)25 (31%) Sabry (2015)Retrospective case seriesInclusion: endonasally operated PA40Median: 48 years (range 18--81)18 (45%)NSVolume: 9.48 cm^3^ (SD 12.7)33 (83%) Wongsirisuwan (2014)Retrospective case seriesInclusion: PA operated with keyhole and endonasal approach (2003--2013)38/130NSNSNSNSNS Zhan (2015)Retrospective case seriesInclusion: PA patients resected endoscopically (2008--2014)313NS125 (39%)NSNS239 (75%)*NS* not specified, *SD* standard deviation, *NF* non-functioning, *ACHT* adrenocorticotrophic hormone, *GH* growth hormone, *TSH* thyroid stimulating hormone, *PRL* prolactinoma, *PA* pituitary adenoma

Visual outcomes {#Sec10}
---------------

Results of postoperative visual outcomes are reported in Supplementary Table 2 for each study. Pooled prevalence rates for visual acuity, visual fields deficits, and unspecified visual functioning are reported in Table [2](#Tab2){ref-type="table"}.

Table 2Outcomes of the meta-analysisFixed model prevalence rate (%)95% CI (%)Random model prevalence rate (%)95% CI (%)I-squared value (%)p value heterogeneityEgger's test (p value)Begg's test (p value)Visual acuity Improvement67.559.1--75.077.254.4--90.686.0\<0.010.220.14 Deterioration4.51.8--10.84.51.8--10.80.000.621.000.49 Complete restoration^a^Visual field deficit Improvement80.877.7--83.683.077.1--87.762.3\<0.010.250.14 Deterioration2.31.1--4.72.31.1--4.70.000.930.210.16 Complete restoration40.434.8--46.337.826.4--50.80.0073.20.720.40Unspecified vision Improvement80.977.9--83.681.777.1--85.638.80.080.100.15 Deterioration2.01.1--3.42.01.1--3.40.000.961.000.74 Complete restoration32.918.5--37.739.623.2--58.684.2\<0.010.500.53^a^Complete restoration of visual acuity was only reported in one study and therefore a meta-analysis was not possible

Visual acuity {#Sec11}
-------------

Patients presented with visual acuity complaints in 14--84% of cases (Supplementary Table 3) \[[@CR5], [@CR36]\]. Ten studies evaluated postoperative visual acuity in their case series \[[@CR5], [@CR6], [@CR9], [@CR20], [@CR22], [@CR25], [@CR30], [@CR36], [@CR37], [@CR46]\]. Pooled prevalence of overall improvement was 67.5% (95% CI: 59.1--75.0%, I^2^: 86.0%, n = 163/219). Pooled prevalence of deterioration was 4.5% (95% CI: 1.8--10.8%, I^2^: 0.00%, n = 3/122) (Table [2](#Tab2){ref-type="table"}). One study reported complete recovery of visual acuity in 9 out of 33 patients \[[@CR46]\]. No significant publication bias was identified. One study described a significant improvement in mean Snellen test score for both the right eye \[preoperative: 0.72 (SD: 0.14); postoperative 0.83 (SD: 0.16); p \< 0.01\] and left eye \[preoperative: 0.76 (SD: 0.16); postoperative 0.85 (SD: 0.14); p = 0.04\] \[[@CR19]\].

Visual field deficit {#Sec12}
--------------------

Patients presented with visual field deficits in 28--100% of cases (Supplementary Table 3) \[[@CR5], [@CR41], [@CR42]\]. Nineteen studies described outcomes of visual field deficits \[[@CR5], [@CR8]--[@CR11], [@CR19]--[@CR23], [@CR27]--[@CR29], [@CR36], [@CR37], [@CR41], [@CR42], [@CR44], [@CR46]\]. The overall prevalence was 40.4% (95% CI: 34.8--46.3%, I^2^: 0.00%, n = 122/346) for complete recovery, 80.8% (95% CI: 77.7--83.6%, I^2^: 62.3%, n = 678/817) for overall improvement, and 2.3% (95% CI: 1.1--4.7%, I^2^: 0.00%, n = 3/398) for deterioration in which patients showed a decreased visual functioning postoperatively (Table [2](#Tab2){ref-type="table"}). One study described a mean Goldmann Humphrey VFD score of 1.1 (SD: 1.1) preoperatively, compared to 0.2 (SD: 0.5) postoperatively, indicating a clear improvement (p \< 0.05) \[[@CR41]\]. No significant publication bias was identified.

Unspecified vision {#Sec13}
------------------

In studies that did not specify type of visual problems, 17--100% of the patients presented with visual problems (Supplementary Table 3) \[[@CR31], [@CR39]\]. Unspecified outcomes of visual improvement were reported in 13 studies \[[@CR24], [@CR26], [@CR31]--[@CR35], [@CR38]--[@CR40], [@CR43], [@CR45], [@CR47]\]. Pooled prevalence for complete recovery was 32.9% (95% CI: 28.5--37.7%, I^2^: 84.2%, n = 139/416). Improvement was reported in 80.9% (95% CI: 77.9--83.6%, I^2^: 38.8%, n = 648/788). Deterioration occurred in 2.0% (95% CI: 1.1--3.4%, I^2^: 0.00%, n = 10/721). No significant publication bias was identified.

Study-quality assessment {#Sec14}
------------------------

The majority of studies (83.3%) had a high risk of bias due to suboptimal methodology or poor reporting (Table [3](#Tab3){ref-type="table"}). While all studies clearly described the surgical approach (exposure of intervention), only one study scored all points for selection and description of included patients and only one study for the description, interpretation, and discussion of the outcomes (outcome assessment) \[[@CR31], [@CR40]\]. However, study quality was associated with visual outcomes in a meta-regression (all p \< 0.05).

Table 3Study quality assessmentAuthor (year)Selection (max. 4 points)Exposure (max. 1 points)Outcome (max. 5 points)Total points (max. 10)Visual acuity and visual field studies Bokhari (2013)2136 Campbell (2010)2136 Chabot (2015)3117 Juraschka (2014)3126 Karppinen (2015)3148 Yildrim (2016)3126Visual acuity studies Constantino (2016) \[[@CR25]\]3115 De Witte (2011) \[[@CR6]\]2125 Fan (2014) \[[@CR30]\]1113Visual field studies Anik (2011) \[[@CR19]\]3148 Akin (2016) \[[@CR10]\]3126 Cappabianca (1999) \[[@CR21]\]2114 Chi (2013) \[[@CR8]\]1124 Cho (2002) \[[@CR23]\]3115 Dallapiazza (2015) \[[@CR28]\]3115 Dehdashti (2008) \[[@CR29]\]2125 D'Haens (2009) \[[@CR27]\]2125 Leach (2010) \[[@CR9]\]1135 Minet (2008) \[[@CR41]\]2136 Nakao (2011) \[[@CR42]\]2136 Paluzzi (2014) \[[@CR11]\]2147 Sheehan (1999) \[[@CR44]\]2136Visual function, unspecified Chohan (2016) \[[@CR24]\]3115 Cusimano (2012) \[[@CR26]\]3115 Gondim (2014) \[[@CR32]\]2157 Gondim (2015) \[[@CR33]\]2114 Ferreli (2014) \[[@CR31]\]3115 Han (2013) \[[@CR34]\]3126 Jho (1997) \[[@CR35]\]3125 Koutourousiou (2013) \[[@CR38]\]2125 Kuo (2016) \[[@CR39]\]3126 Marenco (2011) \[[@CR40]\]4138 Sabry (2015) \[[@CR43]\]2136 Wongsirisuwan (2014) \[[@CR45]\]3115 Zhan (2015) \[[@CR47]\]1124Median scores2 points1 point2 points6 pointsStudies scoring maximum points2.8%100%2.8%

Factors influencing visual outcomes {#Sec15}
-----------------------------------

Factors affecting postoperative visual functioning may be procedure, symptom, tumor or patient related. Regarding procedural circumstances, increasing surgeon experience was positively associated with postoperative visual field deficit improvement in three studies (early groups: 75--86%; late groups: 90--100%) \[[@CR5], [@CR8], [@CR9]\]. Furthermore, extend of resection was associated with poor visual field deficit outcomes in one study (p = 0.01), while three studies found no significant relation, both for visual acuity and visual field deficit outcomes \[[@CR22], [@CR36], [@CR40], [@CR42]\].

Regarding symptoms, longer duration of visual field deficits led to worse visual outcomes in two studies, while one study did not find a relation \[[@CR19], [@CR42]\]. In the first study, patients with complete recovery had a shorter visual field deficit symptoms (14.7 weeks, SD: 10.5), than patients with partial recovery (50.1 weeks, SD: 29.1) and patients with no recovery (92.4 weeks, SD: 15.4) (p \< 0.01) \[[@CR19]\]. Also, one study demonstrated that severity of visual field deficit symptoms was associated with worse visual outcomes in a multivariable analysis \[[@CR48]\]. Finally, patients with bilateral visual field deficit had significantly better outcomes (p = 0.025) \[[@CR22]\].

Regarding tumor related factors, functioning (growth hormone producing tumors: 71%, prolactinomas 63--75%) and non-functioning pituitary tumors (43--100%) seem to have similar visual outcomes with regard to visual field deficits and unspecified visual improvement \[[@CR8], [@CR10], [@CR19], [@CR28], [@CR31], [@CR32], [@CR37], [@CR42], [@CR44], [@CR46]\]. One study found a significant relation between suprasellar extension and worse visual outcomes based on patient reported outcome measures, where another does not find a relation with visual field deficits \[[@CR42], [@CR49]\]. Also, tumor size does not seem to have a great influence on both postoperative visual acuity and visual field deficits as seen in two studies with larger tumors (\>3 cm in diameter and a volume \>10 cm^3^) where improvement was seen in 69 and 70% of cases \[[@CR22], [@CR24]\].

With regard to patient characteristics, the influence of age on visual outcomes shows conflicting results in four studies \[[@CR47]\]. One group reported no significant differences between patients younger and older than 65 for unspecified visual symptoms \[[@CR33], [@CR40], [@CR47], [@CR48]\]. Similarly, two studies reported outcomes of patients older than 65 and 70 years with unspecified visual improvement in 71 and 87% of cases, respectively \[[@CR33], [@CR40]\]. However, one study associated younger age with visual field deficit improvement in a multivariate analysis \[[@CR48]\].

Discussion {#Sec16}
==========

This meta-analysis showed that pituitary adenoma resection in patients with preoperative visual symptoms considerably improves these symptoms in the majority of cases. Furthermore, up to 30% of patients have complete recovery of their vision. However, deterioration is not uncommon either, occurring in up to 4% of cases. While the considerable improvement of visual deficits is a clear indication for EETS in patients with pituitary adenomas, a better understanding of the factors that influence these outcomes may result in even better postoperative results. These factors can be procedure, symptom, tumor, and patient related.

Factors related to the procedure may influence visual outcomes in several ways, such as experience with EETS. Although visual outcomes may improve with increased experience, this may be balanced out by selection of more complex cases. Despite this, surgeon experience was found to be a significant influence on visual outcomes in three studies \[[@CR5], [@CR8], [@CR9]\]. However, gross total resection was not associated with improved visual outcomes, probably because also partial resection will result in decompression of the optic nerve/chiasm \[[@CR22], [@CR36], [@CR40], [@CR42]\]. Besides surgeon experience, surgeon preference for preventive surgery or surgery after development of visual deficits may also result in different outcomes.

Apart from procedure related factors, the duration and severity of preoperative visual symptoms may also affect postoperative outcomes \[[@CR19], [@CR48], [@CR50]\]. For instance, one study found that patients with long lasting (≥1 year) preoperative visual symptoms showed significantly worse visual outcomes after microscopic resection \[[@CR50]\]. As the timing of the postoperative visual examination varied greatly among the studies and visual symptoms may improve after longer periods of time, this may also be of influence \[[@CR9]--[@CR11], [@CR22], [@CR31], [@CR34], [@CR37], [@CR43], [@CR51], [@CR52]\].

Several patient and tumor characteristics may also affect visual outcomes. Increasing age does not seem to be associated with worse outcomes \[[@CR33], [@CR40], [@CR47], [@CR48]\]. Tumor size and whether the tumor is hormone producing does not seem to greatly alter the visual outcomes \[[@CR10], [@CR20], [@CR22]--[@CR25], [@CR36], [@CR38], [@CR39]\]. The lack of influence from tumor size on visual outcomes may possibly be explained by the slow growth of these tumors, which gives the optic nerve/chiasm time to adapt. However, indication and aim of surgery for functioning and non-functioning pituitary adenomas differs principally, as surgical indication for functioning pituitary adenomas is often not visual deficits. Therefore, different visual outcomes of surgery may be expected when comparing these two groups.

One other meta-analysis for pituitary adenomas by DeKlotz et al. reported an overall visual improvement of 71% (95% CI: 59--83%) in patients operated endoscopically based on nine studies, which is similar to our findings. This was also significantly higher than the patients operated microscopically (56%, 95% CI: 40--72%) \[[@CR53]\].

Several other tumors in the sellar region may cause impaired vision. Patients with meningiomas showed improvement of vision after endoscopic resection in 87% of cases in one meta-analysis \[[@CR54]\]. Another review evaluating anterior skull base meningiomas reported improvement in 69.1% of cases, but deterioration in 12.7% of cases, the latter being considerably higher than our findings \[[@CR55]\]. A meta-analysis of visual outcomes after endoscopic surgery for craniopharyngioma showed improvement in 56.2% and deterioration 1.7% of cases \[[@CR56]\]. Similarly, another meta-analysis for craniopharyngiomas even found an improvement in 85.5% of cases and deterioration in 2.3% \[[@CR57]\]. With regard to this variation in results, it is not entirely unlikely that different tumors with different characteristics offer different visual outcomes after endoscopic resection. As a result, while meningioma resection seems to be associated with superior visual outcomes compared pituitary adenoma resection, craniopharyngioma resection seems to offer slightly inferior outcomes \[[@CR54], [@CR56], [@CR57]\].

While there are over 30 existing questionnaires measuring patient-reported visual function and vision-related HRQoL, no studies were identified measuring these outcomes in endoscopically operated pituitary patients \[[@CR58]\]. Measurement of patient-reported visual function and HRQoL is of added value as it is known that physician-reported outcomes and patient-reported outcomes may poorly correlate and because these questionnaires measure not only visual deficits but also consequences of these deficits on daily life \[[@CR59]\].

The main limitation of this meta-analysis is the inability to examine reported patient characteristics as a possible source of heterogeneity, because not all pituitary adenoma patients present with visual problems. Patient characteristics were reported for the whole population, not specifically for patient presenting with visual symptoms. Thus, no clear factors were identified that could contribute to better outcomes. Furthermore, as the studies identified only described visual recovery with relatively short follow-up, long-term visual outcomes could not be studied.

Even though our study shows that EETS for pituitary adenoma improves visual complaints for most patients, incomplete recovery or even worsening of symptoms is not uncommon. Therefore, future research should be focused on identifying risk factors for incomplete recovery or even deterioration of vision with adequate follow-up. The role of surgical experience, patient characteristics, tumor characteristics, and severity and duration of visual symptoms should be studied (preferably prospectively) to identify the optimal timing of, and indications for, EETS for pituitary adenomas.

Conclusion {#Sec17}
==========

ETTS for pituitary adenomas improves visual deficits considerably in the majority of cases in the postoperative period. However, EETS only results in complete recovery in 30--40% of cases and 4% of patients even experience deterioration of visual symptoms. This is particularly relevant, as visual symptoms often form the indication of surgery. Future research should therefore focus on identifying risk factors for incomplete recovery and deterioration of vision in order to improve visual outcomes.
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